Why This Gene Therapy Pioneer Crashed 29.8% in December – Motley Fool
Greensburg Daily News |
Why This Gene Therapy Pioneer Crashed 29.8% in December
Motley Fool At the American Society of Hematology conference in early December, both Spark Therapeutics and BioMarin reported impressive results from ongoing hemophilia A trials evaluating one-and-done gene therapies that restore a patients' ability to produce … Price of gene therapy for rare form of blindness: $850K Gene Therapy For Rare Forms Of Blindness Will Cost Nearly Half A Million Per Eye |
